Fig. 2.

Targeting JOSD1 significantly suppresses gynaecological cancer growth in vivo. a–d In vivo growth and tumour weights of xenografts generated from A2780 (n = 6 for each group) and HeLa (n = 8 for each group) cells expressing either short hairpin RNAs (shRNAs) targeting JOSD1 or nontargeting shRNA. e In vitro growth of eight gynaecological cancer primary cell lines transfected with either small interfering RNAs targeting JOSD1 or negative control siRNA. f Tumour weights of ovarian cancer patient-derived xenograft models administered adeno-associated virus (AAV) targeting JOSD1 or AAV with a nontargeting sequence (n = 5 per group). Two-tailed Student’s t test; *p < 0.05, **p < 0.01 and ****p < 0.0001. For a–d and f, the data are presented as the mean ± SEM. For e, the data are presented as the mean ± SD, and representative results of three biological replicates are shown